A phase 1/2 trial of tersolisib (LY4064809/STX-478), a pan-mutant-selective PI3Kα inhibitor (PI3Kαi), in PIK3CA -mutant advanced solid tumors: Updated results from PIKALO-1.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Komal L. Jhaveri, Alberto J. Montero, Antoine Italiano, Antonio Giordano, Amita Patnaik, Gennaro Daniele, Jordi Rodon Ahnert, Pamela N. Munster, Giuseppe Curigliano, Cristina Saura Manich, Austin G. Duffy, Robert Wesolowski, Jorge Bartolome Arcilla, Isabelle Laure Ray-Coquard, David B. Page, Aixa Elena Soyano Muller, Gertjan van Hal, Lin Du, Negin Ashki, Dejan Juric
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, University Hospitals Seidman Cancer Center, Case Western Reserve University, Université de Bordeaux, Harvard University, Dana-Farber Cancer Institute, South Texas Accelerated Research Therapeutics, Agostino Gemelli University Polyclinic, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, University of Milan, European Institute of Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Hospital Clínico San Carlos, Centre Léon Bérard, Providence Portland Medical Center, Moffitt Cancer Center, Eli Lilly (United States), Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W7162536296